Abstract:e21210 Background: Molecular profiling is limited by tumor heterogeneity and access to sufficient tissue for comprehensive analysis. ctDNA is promising as a minimally-invasive liquid biopsy for testing gene alterations and monitoring personalised treatment strategies. Because of its high expense, translation of the sensitive and accurate next generation sequencing (NGS) into routine cancer care has been slow. Methods: We retrospectively reviewed 60 advanced NSCLC pts who were performed gene test prior to treatment using tissue by ARMS. Blood collections were performed after disease progression and analysed by NGS using a 10-gene panel (EGFR, KRAS, BRAF, HER2, PIK3CA, ALK, ROS1, RET, MET and TP53). We evaluated the significance of the outcome of panel testing by NGS in guiding the subsequent treatment in clinical practice. Results: ctDNA profiling detected alterations in 50 pts (83%). TP53 (53%), EGFR (48%) and KRAS (15%) were the most common abnormalities detected. Additionally, MET (8%), ALK (3%), HER2 (3%) and PIK3CA (2%) mutations were detected, respectively. Sensitizing mutations were detected in 22 pts (37%) prior to treatment using tissue by the method of ARMS, including 20 EGFR mutations and 2 ALK fusions, and all pts received tyrosine kinase inhibitor (TKI) as first-line therapy. Among 20 EGFR mutant pts, T790M mutation was detected in 9 pts (45%), KRAS mutation was detected in 4 pts (20%), and TP53 mutation was detected in 12 pts (60%), while MET amplification was found in 1 pt (5%). 1 KRAS mutation and 1 TP53 mutation were detected in 2 ALK –TKI resistant pts, respectively. 28 pts (47%) reported as tissue negative had a positive liquid biopsy, including 4 MET 14 exon skipping mutations, 2 EGFR 19 DEL, 4 EGFR L858R and 1 EGFR L861Q, and 2 EGFR T790M mutations. The mutation abundance is all below 1%, except 2 EGFR 19 DEL and 4 L858R. Ten pts received TKIs; 2 got parcial responses, 5 stable diseases and 3 progressive disease. Conclusions: ctDNA can be used as a ‘liquid biopsy’ for NSCLC pts, and NGS, as a highly sensitive method to detect mutations with low mutation abundance, can provide more chances to pts to receive precise treatment.

Evaluation of the IdyllaTM EGFR Mutation Test on formalin-fixed, paraffin-embedded tissue of human lung cancer

Evaluation of the Idylla™ EGFR Mutation Test on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.

Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients

Ultra-rapid Idylla? <i>EGFR</i> mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Comparison of Cross-Platform Technologies for EGFR T790M Testing in Patients with Non-Small Cell Lung Cancer

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

ARMS for EGFR Mutation Analysis of Cytologic and Corresponding Lung Adenocarcinoma Histologic Specimens

Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform: a real-world two-center experience in Greece

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

A Comparison of ARMS and Direct Sequencing for EGFR Mutation Analysis and Tyrosine Kinase Inhibitors Treatment Prediction in Body Fluid Samples of Non-Small-Cell Lung Cancer Patients

Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

Immunohistochemical Detection of Mutations in the Epidermal Growth Factor Receptor Gene in Lung Adenocarcinomas Using Mutation-Specific Antibodies.

Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing

Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC

Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study